{
    "root": "7125d234-570f-4c51-8e72-8202f4dc299b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FEBUXOSTAT",
    "value": "20230614",
    "ingredients": [
        {
            "name": "FEBUXOSTAT",
            "code": "101V0R1N2E"
        },
        {
            "name": "ALUMINUM OXIDE",
            "code": "LMI26O6933"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Febuxostat tablets are a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. \n                  \n                     Limitations of Use: \n                  \n                  Febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia.",
    "contraindications": "• Recommended dosage is 40 mg or 80 mg once daily. The recommended starting dosage is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg/dL after 2 weeks, the recommended dosage is 80 mg once daily. ( 2.1 ) • Patients with severe renal impairment: Limit the dosage to 40 mg once daily. ( 2.2 , 8.6 ) • Flare prophylaxis is recommended upon initiation of febuxostat tablets. ( 2.4 ) • Can be administered without regard to food or antacid use. ( 2.1 )",
    "warningsAndPrecautions": "Febuxostat 40 mg tablets are light green to green round biconvex film coated tablets, debossed with “284” on one side and “S” on the other side and supplied as:\n                  \n                     \n                        NDC Number Size\n                     \n                  \n                  43547-295-03 Bottle of 30 Tablets\n                  43547-295-09 Bottle of 90 Tablets\n                  43547-295-50 Bottle of 500 Tablets\n                  Febuxostat 80 mg tablets are light green to green oval biconvex film coated tablets, debossed with “296” on one side and “S” on the other side and supplied as:\n                  \n                     \n                        NDC Number Size\n                     \n                  \n                  43547-296-03 Bottle of 30 Tablets\n                  43547-296-09 Bottle of 90 Tablets\n                  43547-296-50 Bottle of 500 Tablets\n                  Protect from light. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions": "Febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7)]."
}